User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 23:14, 16 October 2018 (diff | hist) . . (-58) . . m Multiple myeloma, relapsed/refractory (→Chemotherapy) (current)
- 23:13, 16 October 2018 (diff | hist) . . (-2) . . m Multiple myeloma, induction (→Chemotherapy) (current)
- 23:10, 16 October 2018 (diff | hist) . . (+26) . . m HIV-associated lymphoma (→Chemotherapy) (current)
- 23:08, 16 October 2018 (diff | hist) . . (-54) . . m Waldenström macroglobulinemia (current)
- 23:07, 16 October 2018 (diff | hist) . . (-28) . . m Waldenström macroglobulinemia (→Chemotherapy)
- 23:05, 16 October 2018 (diff | hist) . . (-12) . . m Allogeneic HSCT (→Supportive medications) (current)
- 23:04, 16 October 2018 (diff | hist) . . (-34) . . m Allogeneic HSCT (→Chemotherapy)
- 23:01, 16 October 2018 (diff | hist) . . (-38) . . m B-cell acute lymphoblastic leukemia (→Chemotherapy) (current)
- 22:57, 16 October 2018 (diff | hist) . . (-32) . . m Burkitt lymphoma (current)
- 22:54, 16 October 2018 (diff | hist) . . (-19) . . m Multiple myeloma, relapsed/refractory (→Chemotherapy)
- 22:19, 16 October 2018 (diff | hist) . . (-2) . . m Hemophagocytic lymphohistiocytosis (→Initial therapy) (current)
- 22:17, 16 October 2018 (diff | hist) . . (+1,469) . . Breast cancer, BRCA-mutated (→Metastatic disease, all lines of therapy) (current)
- 22:09, 16 October 2018 (diff | hist) . . (+1) . . m Talazoparib (Talzenna) (current)
- 22:09, 16 October 2018 (diff | hist) . . (+615) . . N Talazoparib (Talzenna) (Created page with "==Mechanism of action== PARP inhibitor ==Diseases for which it is used== *BRCA-mutated breast cancer ==History of changes in FDA indication==...")
- 22:06, 16 October 2018 (diff | hist) . . (+6) . . m Drug index (→T) (current)
- 22:03, 16 October 2018 (diff | hist) . . (-61) . . m Neuroendocrine tumors (→Endocrine & Immunotherapy) (current)
- 22:01, 16 October 2018 (diff | hist) . . (+46) . . m Multiple myeloma - historical (current)
- 22:00, 16 October 2018 (diff | hist) . . (+23) . . m Chronic myelogenous leukemia (→Chemoimmunotherapy) (current)
- 21:56, 16 October 2018 (diff | hist) . . (-74) . . m Ibritumomab tiuxetan (Zevalin) (current)
- 21:56, 16 October 2018 (diff | hist) . . (-16) . . m Autologous HSCT (current)
- 21:55, 16 October 2018 (diff | hist) . . (-1) . . m Marginal zone lymphoma (current)
- 21:54, 16 October 2018 (diff | hist) . . (-8) . . m Mantle cell lymphoma (current)
- 21:53, 16 October 2018 (diff | hist) . . (-3) . . m Follicular lymphoma (current)
- 21:51, 16 October 2018 (diff | hist) . . (-8) . . m Diffuse large B-cell lymphoma (current)
- 21:48, 16 October 2018 (diff | hist) . . (-4) . . m Acute myeloid leukemia (current)
- 21:45, 16 October 2018 (diff | hist) . . (-67) . . m Transformed lymphoma (current)
- 21:42, 16 October 2018 (diff | hist) . . (+80) . . m Primary mediastinal B-cell lymphoma (→Supportive medications) (current)
- 21:41, 16 October 2018 (diff | hist) . . (+79) . . m Diffuse large B-cell lymphoma (→Supportive medications)
- 21:40, 16 October 2018 (diff | hist) . . (+213) . . m Acute myeloid leukemia (→Chemotherapy)
- 21:28, 16 October 2018 (diff | hist) . . (-5) . . m Small cell lung cancer (→Chemotherapy) (current)
- 21:26, 16 October 2018 (diff | hist) . . (-52) . . m Mantle cell lymphoma (→Chemotherapy)
- 21:25, 16 October 2018 (diff | hist) . . (-98) . . m Small cell lung cancer (→Chemoradiotherapy)
- 21:17, 16 October 2018 (diff | hist) . . (-68) . . m Ewing's sarcoma (current)
- 21:13, 16 October 2018 (diff | hist) . . (-54) . . m Acute myeloid leukemia
- 21:08, 16 October 2018 (diff | hist) . . (-94) . . m Hodgkin lymphoma - historical (→Dose modifications) (current)
- 21:06, 16 October 2018 (diff | hist) . . (-4) . . m Burkitt lymphoma
- 21:04, 16 October 2018 (diff | hist) . . (+3) . . m Large granular lymphocytic leukemia (→Chemotherapy) (current)
- 21:04, 16 October 2018 (diff | hist) . . (+1) . . m B-cell acute lymphoblastic leukemia (→Chemotherapy)
- 21:03, 16 October 2018 (diff | hist) . . (-2) . . m Breast cancer (→Chemotherapy) (current)
- 21:02, 16 October 2018 (diff | hist) . . (-22) . . m Acute myeloid leukemia
- 20:59, 16 October 2018 (diff | hist) . . (-10) . . m Small cell lung cancer
- 20:57, 16 October 2018 (diff | hist) . . (-77) . . m Mantle cell lymphoma
- 20:53, 16 October 2018 (diff | hist) . . (+121) . . m Follicular lymphoma - historical (→MCP {{#subobject:5510fa|Regimen=1}}) (current)
- 20:51, 16 October 2018 (diff | hist) . . (+36) . . m Follicular lymphoma (→R-MCP {{#subobject:2a4e31|Regimen=1}})
- 20:50, 16 October 2018 (diff | hist) . . (+53) . . m Mantle cell lymphoma (→MCP {{#subobject:a84c0e|Regimen=1}})
- 20:50, 16 October 2018 (diff | hist) . . (+45) . . m Marginal zone lymphoma (→MCP {{#subobject:1cc3da|Regimen=1}})
- 20:47, 16 October 2018 (diff | hist) . . (-3) . . m Multiple myeloma, relapsed/refractory (→Variant #4, 20/27 dosing, with BSA cap {{#subobject:166b4f|Variant=1}})
- 20:45, 16 October 2018 (diff | hist) . . (-10) . . m Ovarian cancer (→Chemotherapy) (current)
- 20:43, 16 October 2018 (diff | hist) . . (+3) . . m Hodgkin lymphoma (→Chemotherapy) (current)
- 11:53, 16 October 2018 (diff | hist) . . (+27) . . m Colon cancer (current)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
